NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$26.69 USD
-0.04 (-0.15%)
Updated Sep 19, 2025 03:59 PM ET
After-Market: $26.74 +0.05 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
NewAmsterdam Pharma Company N.V.'s return on equity, or ROE, is -27.28% compared to the ROE of the Medical - Drugs industry of -59.18%. While this shows that NAMS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
NAMS 26.69 -0.04(-0.15%)
Will NAMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
NAMS Crossed Above 20 Day Moving Average on September 18
20 Day Moving Average Resistance appears for NAMS after 0.12% move
Director Makes Strategic Move with NewAmsterdam Pharma Stock Purchase
Is NAMS positioned for a breakout? 50 Day Moving Average Support shows up after advancing 1.66%
NAMS forms 50 Day Moving Average Support on September 15